News

During May, the Allergen Bureau participated in the Woolworths Group Technical Supplier Forums held across Sydney, Brisbane, Melbourne and Perth. These forums play an important role in strengthening quality and risk management across the supply chain by creating opportunities to…

The Global Food Safety Initiative (GFSI) Conference 2026, held in Vancouver and marking 25 years of Global Food Safety Initiative, brought together 600 delegates to explore the evolving food safety landscape. Key themes—including digital transformation, audit evolution, risk-based approaches, and…

A series of food recalls issued in March and early April 2026 triggered by undeclared allergens has again highlighted the ongoing challenges of allergen management in food manufacturing and labelling.   According to official recall notices published by food regulators,…

People living with coeliac disease are often encouraged to increase their fibre intake to support gut health, either through diet or supplements. However, new research from McMaster University suggests fibre alone may not deliver the expected benefits unless the gut contains the bacteria needed…

From egg‑free mayonnaise to yeast‑derived milk, Japanese food companies are looking to reshape how allergen‑free products are positioned — not as compromises, but as everyday choices with broader appeal.  Japanese media outlet Japan Forward has reported on this trend alongside statistics on food allergy in Japan, noting that despite growing availability, allergen‑free foods…

The prescription-only peanut allergy treatment Palforzia® will be discontinued on 31 July 2026, according to its manufacturer, Stallergenes Greer. The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2020.  Palforzia is the only oral immunotherapy approved by the FDA for the treatment…